D0079 | Meloxicam

Molecular Formula C14H13N3O4S2
Molecular Weight 351.4
State solid
Clearance * 8.8 mL/min [Healthy Male Adults (Fed) oral 7.5 mg tablets] * 9.9 mL/min [Eldery Male (Fed) oral 15 mg capsules] * 5.1 mL/min [Eldery Female (Fed) oral 15 mg capsules] * 19 mL/min [Renal Failure (Fasted) oral 15 mg capsules] * 11 mL/min [Hepatic Insufficiency (Fasted) oral 15 mg capsules]
Volume of distribution * 10 L
Route of elimination Meloxicam is almost completely metabolized to four pharmacologically inactive metabolites. Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively.
Protein binding 99.4% bound, primarily to albumin
Half life 15-20 hours
Absorption Absolute bioavailability = 89%
Trade names Mobic
Description nonsteroidal anti-inflammatory drug (NSAID); blocks cyclooxygenase-2 (COX-2) ; oxicam family; analgesics;


M01AC56 Meloxicam, combinations

[M01AC] Oxicams



[M] Musculoskeletal system

M01AC06 Meloxicam

[M01AC] Oxicams



[M] Musculoskeletal system

Toxicity Dose Time Species Model Method Action Positive criterion Reference
TRANSMEMBRANE POTENTIAL 382 24hr rat hepatocytes tetramethylrhodamine ethyl ester (TMRE) decrease AC50 (μM) 40
MEMBRANE POTENTIAL 14.47±0.00 human qHTS-HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL human HepG2 MMP assay Negative IC50 163
MEMBRANE POTENTIAL rat hepatocytes MMP assay Negative IC50 163
STATE 2 RESPIRATION 22.8 ± 2.8 rat isolated rat liver mitochondria State 2 respiration ( 96-well plate format using a phosphorescent oxygen-sensitive probe MitoXpress) inhibit UC50 (nmol/mg mitochondrial protein) 40
STATE 3 RESPIRATION 100 nmol/mg mitochondrial protein rat isolated rat liver mitochondria State 3 respiration ( 96-well plate format using a phosphorescent oxygen-sensitive probe MitoXpress) Negative IC50 (nmol/mg mitochondrial protein) 40
LIPID METABOLISM > 500 24hr rat hepatocytes LipidTox, for neutral lipid accumulation, to evaluate lipid content. accumulation AC50 (μM) 40
GLUTATHIONE METABOLISM 316 24hr rat hepatocytes glutathion depletion: cells were incubated with 50 μM monochlorobimane with 6 μg/ml Hoechst 33342 AC50 (μM) 40
ROS PRODUCTION NR rat hepatocytes use CM-H2DCFDA to monitor reactive oxygen species Negative AC50 (μM) 40
CYTOCHROME C RELEASE 245 24hr rat hepatocytes cytochrome c release (anti-cytochrome c antibody ) induce AC50 (μM) 40
ER STRESS-INDUCED 153 24hr rat hepatocytes DNA damage 153 induction (GADD153 antibodies) for ER-stress induced apoptosis induce AC50 (μM) 40

Pictogram Signal Statements Precautionary Statement Codes

H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]

P260, P264, P270, P314, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

  • Acute coronary syndrome

  • Arthritis

  • Arthropathy

  • Cerebrovascular accident

  • Gastrointestinal disorder

  • Inflammation

  • Juvenile idiopathic arthritis

  • Myocardial infarction

  • Pain

  • Rheumatoid arthritis

  • Abdominal pain

  • Abdominal pain upper

  • Accident at home

  • Anaemia

  • Angiopathy

  • Arthralgia

  • Arthritis

  • Asthenia

  • Back pain

  • Blood urea increased

  • Bronchitis

  • Bursitis

  • Carpal tunnel syndrome

  • Cataract

  • Connective tissue disorder

  • Constipation

  • Cough

  • Creatinine renal clearance decreased

  • Dehydration

  • Dermatitis

  • Diarrhoea

  • Dizziness

  • Dry mouth

  • Dyspepsia

  • Dyspnoea

  • Ear disorder

  • Eructation

  • Eye disorder

  • Fatigue

  • Flatulence

  • Gastritis

  • Gastrointestinal disorder

  • Gastrointestinal haemorrhage

  • Gastrointestinal pain

  • Gastrooesophageal reflux disease

  • Gravitational oedema

  • Haematuria

  • Headache

  • Hepatic function abnormal

  • Hepatobiliary disease

  • Hyperhidrosis

  • Hypersensitivity

  • Hypertension

  • Immune system disorder

  • Increased appetite

  • Infection

  • Infestation

  • Influenza

  • Influenza like illness

  • Insomnia

  • Malnutrition

  • Mediastinal disorder

  • Melaena

  • Mental disorder

  • Mouth ulceration

  • Muscle spasms

  • Musculoskeletal discomfort

  • Myalgia

  • Nasopharyngitis

  • Nausea

  • Nervous system disorder

  • Oedema

  • Oedema peripheral

  • Pain

  • Pain in extremity

  • Pharyngitis

  • Pleuritic pain

  • Pollakiuria

  • Pruritus

  • Purpura

  • Rash

  • Rash erythematous

  • Red blood cell abnormality

  • Rheumatoid arthritis

  • Rhinitis

  • Sinusitis

  • Skin disorder

  • Somnolence

  • Stomatitis

  • Tinnitus

  • Upper respiratory tract infection

  • Urethral disorder

  • Urinary tract disorder

  • Urinary tract infection

  • Vascular purpura

  • Vertigo

  • Visual impairment

  • Vomiting

  • (3Z)-2-methyl-3-[[(5-methyl-1,3-thiazol-2-yl)amino]-oxidanyl-methylidene]-1,1-bis(oxidanylidene)-1$l^{6},2-benzothiazin-4-one (3Z)-3-[hydroxy-[(5-methyl-2-thiazolyl)amino]methylidene]-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazin-4-one (E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2,3-dihydro-4H-benzo[e][1,2]thiazin-4-one 1,1-dioxide
    1027136-06-6 125M387 133687-22-6
    2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide 3-{hydroxy[(5-methyl-1,3-thiazol-2-yl)amino]methylidene}-2-methyl-2,3-dihydro-4H-1,2-benzothiazin-4-one 1,1-dioxide
    4-Hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide 4-Hydroxy-2-methyl-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide 4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazin-3-crboxamide 1,1-dioxide
    4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide 4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide
    4-hydroxy-2-mehtyl-N-(5-mehtyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide 4-hydroxy-2-methyl-N-(5-methy-2-thiazolyl)-2H-1,2-benzothiazine-3-caboxamide-1,1-dioxide 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide
    4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1?^{6},2-benzothiazine-3-carboxamide 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1$l^{6},2-benzothiazine-3-carboxamide 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1lambda6,2-benzothiazine-3-carboxamide
    4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide 4-hydroxy-2-methyl-N-(5-methyl-2-thiazole)-2H-1,2-benzothiazine-3 -carboxamide 1,1-dioxide 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
    71125-38-7 A837087 AB0007297
    AB00383033-17 AB00383033-18 AB00383033_20
    AB1009494 AC-1325 AK-77454
    AKOS000279442 AKOS026749959 ALBB-027268
    AN-668/13244001 ANW-57553 BBL029076
    BB_SC-04648 BCP11928 BDBM50056998
    BG0248 BIDD:GT0726 BSPBio_002257
    C-20653 C08169 C14H13N3O4S2
    CAS-71125-38-7 CC-30198 CCG-39098
    CCRIS 9139 CHEBI:6741 CHEMBL1741042
    CHEMBL599 CPD000718800 CS-2247
    CTK6C3599 CTK6C3600 Coxflam
    Coxicam D00969 DB-055490
    DB00814 DSSTox_CID_803 DSSTox_GSID_20803
    DSSTox_RID_75796 DTXSID1020803 EN300-52507
    ETI-511 F2173-0387 FT-0082769
    FT-0628193 GTPL7220 HMS1922D19
    HMS2089B18 HMS2096I19 HMS2234P07
    HMS2236C09 HMS3259H06 HMS3372C13
    HMS3372P18 HMS3655K06 HMS3713I19
    HMS3744K09 HSCI1_000045 HSDB 7741
    HY-B0261 J10218 KBio2_002113
    KBio2_004681 KBio2_007249 KBio3_001477
    KBioGR_001234 KBioSS_002113 KS-00000JN4
    KS-1084 LS-40538 Lopac0_000766
    M1959 MCULE-4138373089 MFCD00868752
    MLS000028587 MLS001304725 MLS001306413
    MLS006011422 MXM Melfax
    Melonex Meloxicam (JAN/USAN/INN) Meloxicam (Mobic)
    Meloxicam 1.0 mg/ml in Dimethyl Sulfoxide Meloxicam [USAN:BAN:INN] Meloxicam [USAN:USP:INN:BAN]
    Meloxicam(Mobic) Meloxicam, 99-101% Meloxicam,(S)
    Meloxicamum Meloxicamum [Latin] Meloxivet
    Metacam Mobec Mobic
    Mobic (TN) Mobicox Movalis
    Movatec N-1539 NC00698
    NCGC00018248-01 NCGC00018248-02 NCGC00018248-03
    NCGC00018248-04 NCGC00018248-05 NCGC00018248-06
    NCGC00018248-07 NCGC00018248-08 NCGC00022924-03
    NCGC00022924-04 NCGC00256316-01 NCGC00259238-01
    NCGC00263878-02 Opera_ID_2 Parocin
    Q414028 R3928 RTR-031220
    Revmoksikam SAM002589991 SC-12165
    SCHEMBL33369 SCHEMBL3576 SCHEMBL713100
    SMP2_000133 SMR000058994 SMR000718800
    SPBio_000902 SPECTRUM1504150 SR-01000003132-10
    ST24023559 STK620505 SW219562-1
    Spectrum2_000941 Spectrum3_000649 Spectrum4_000787
    Spectrum5_001813 Spectrum_001633 Tenaron
    Tox21_111734 Tox21_111734_1 Tox21_113192
    Tox21_201689 Tox21_302756 UH-AC 62XX
    Vivlodex Z1695493323 ZINC103620661
    meloxicam miloxicam s1734

    DrugBank Name Meloxicam
    DrugBank DB00814
    CAS Number 133687-22-6, 71125-38-7
    PubChem Compound 54677470
    KEGG Compound ID C08169
    KEGG Drug D00969
    PubChem.Substance 46506624
    ChEBI 6741
    PharmGKB PA450353
    ChemSpider 10442740
    BindingDB 50056998.0
    TTD DAP000971
    Wikipedia Meloxicam
    DPD 11764

    1. Dykens et al. (2007)
    2. Moreno-Sanchez et al. (1999)
    3. Vuda et al. (2016)